

SYNTREG

No registrations found.

Ethical review	Positive opinion
Status	Recruitment stopped
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON22553

Source

NTR

Brief title

SYNTREG

Health condition

Immune modulatory activity of a pre-probiotic blend in healthy adult volunteers

Sponsors and support

Primary sponsor: Nutricia Research BV

Source(s) of monetary or material Support: Nutricia Research BV

Intervention

Outcome measures

Primary outcome

Change from baseline in IL-10 production and/or forkhead box protein 3 (Foxp3) expressing cells after 8 weeks of daily study product intake.

Secondary outcome

- Change from baseline in IL-10 production and/or Foxp3 expressing cells after 2 weeks of daily study product intake

- Change from baseline in the levels of several cytokines and prostaglandin E2 (PGE2) and fatty acid composition after 2 and 8 weeks of daily study product intake
- Adverse events (AEs), gastrointestinal (GI) tolerance, stool frequency, consistency and colour.

Study description

Background summary

Not yet available

Study objective

H0: The effect of product A is equal to the effect of product B with respect to change from baseline after 8 weeks of study product intake in IL-10 production [pg/mL] AND in Foxp3 expressing cells.

H1: The effect of product A is unequal to the effect of product B with respect to change from baseline after 8 weeks of study product intake in IL-10 production [pg/mL] OR in Foxp3 expressing cells.

Study design

V1 (Day 1); V2 (Day 14); V3 (Day 56)

Intervention

Duration of intervention: 8 weeks

Intervention group: A pre-probiotic blend and maltodextrose

Control group: maltodextrose

Contacts

Public

Nutricia Research B.V.

Monique Visser

PO Box 80141

Utrecht 3508 TC
The Netherlands
+31-30-2095000
Scientific
Nutricia Research B.V.

Monique Visser
PO Box 80141

Utrecht 3508 TC
The Netherlands
+31-30-2095000

Eligibility criteria

Inclusion criteria

- Age ≥ 18 and ≤ 40 years
- Written informed consent
- Willingness and ability to comply with the study protocol
- Body Mass Index (BMI) ≥ 18.5 and ≤ 24.9 kg/m²
- Non-smoking or stopped smoking for at least 3 months prior to Visit 1 (randomisation)
- Regular stool (stool frequency of at least 1 stool in 3 days)
- Judged by the investigator to be in good health

Exclusion criteria

- Any medical condition that interferes with GI function (e.g irritable bowel syndrome, short bowel syndrome, inflammatory bowel disease, gastric ulcer, gastritis (gastro)enteritis)
- Constipation and/or diarrhoea within 1 week prior to Visit 1 (randomisation)
- Any known allergy and/or intolerance (e.g. coeliac disease, gluten intolerance, allergy to one of the ingredients of the study product)
- Any known renal or hepatic failure

- (History of) any immunological disease and/ or immunodeficiency
- (History of) any cancer with the exception of basal cell carcinoma
- Use of prokinetics, laxatives, antidiarrhoeals, corticosteroids, proton-pump inhibitors (or other gastric acid reducers), immunosuppressants or any active allergy treatment within 3 weeks of Visit 1 (randomisation)
- (History of) any chemotherapy or immunotherapy
- Use of antibiotics within 3 months of screening

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	21-02-2017
Enrollment:	30
Type:	Actual

IPD sharing statement

Plan to share IPD: No

Ethics review

Positive opinion	
Date:	14-02-2017
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL6095
NTR-old	NTR6242
Other	Stichting BEBO : 15AL89652

Study results

Summary results

No